Known limitations of unfractionated heparin (UFH) have encouraged the evaluation of anticoagulant aptamers as alternatives to UFH in highly procoagulant settings such as cardiopulmonary bypass (CPB). Despite progress, these efforts have not been totally successful. We take a different approach and explore whether properties of an anticoagulant aptamer can complement UFH, rather than replace it, to address shortcomings with UFH use. Combining RNA aptamer 11F7t, which targets factor X/Xa, with UFH (or low molecular weight heparin) yields a significantly enhanced anticoagulant cocktail effective in normal and COVID-19 patient blood. This aptamer-UFH combination (1) supports continuous circulation of human blood through an ex vivo membrane oxygenation circuit, as is required for patients undergoing CPB and COVID-19 patients requiring extracorporeal membrane oxygenation, (2) allows for a reduced level of UFH to be employed, (3) more effectively limits thrombin generation compared to UFH alone, and (4) is rapidly reversed by the administration of protamine sulfate, the standard treatment for reversing UFH clinically following CPB. Thus, the combination of factor X/Xa aptamer and UFH has significantly improved anticoagulant properties compared to UFH alone and underscores the potential of RNA aptamers to improve medical management of acute care patients requiring potent yet rapidly reversible anticoagulation.
Get full access to this article
View all access options for this article.
References
1.
GunaratneR, KumarS, FrederiksenJW, StayrookS, LohrmannJL, PerryK, BompianiKM, ChabataCV, ThaljiNK, et al. (2018). Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. Nat Biotechnol, 36:606–613.
2.
SniecinskiRM and LevyJH. (2015). Anticoagulation management associated with extracorporeal circulation. Best Pract Res Clin Anaesthesiol, 29:189–202.
3.
BrufattoN, WardA and NesheimME. (2003). Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost, 1:1258–1263.
4.
HepnerM and KarlaftisV. (2013). Antithrombin. Methods Mol Biol, 992:355–364.
5.
MerliniPA, ArdissinoD, BauerKA, OltronaL, PezzanoA, BottassoB, RosenbergRD and Mannucci.PM (1997). Persistent thrombin generation during heparin therapy in patients with acute coronary syndromes. Arterioscler Thromb Vasc Biol, 17:1325.
6.
FinleyA and GreenbergC. (2013). Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg, 116:1210–1222.
7.
DayJR and TaylorKM. (2005). The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg, 3:129–140.
8.
ChabataCV, FrederiksenJW, SullengerBA and GunaratneR. (2018). Emerging applications of aptamers for anticoagulation and hemostasis. Curr Opin Hematol, 25:382–388.
9.
NimjeeSM, WhiteRR, BeckerRC and SullengerBA. (2017). Aptamers as Therapeutics. Annu Rev Pharmacol Toxicol, 57:61–79.
10.
NimjeeSM, PovsicTJ, SullengerBA and BeckerRC. (2016). Translation and clinical development of antithrombotic aptamers. Nucleic Acid Ther, 26:147–155.
11.
NimjeeSM, OneyS, VolovykZ, BompianiKM, LongSB, HoffmanM and SullengerBA. (2009). Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin. RNA, 15:2105–2111.
12.
RusconiCP, ScardinoE, LayzerJ, PitocGA, OrtelTL, MonroeD and SullengerBA. (2002). RNA aptamers as reversible antagonists of coagulation factor IXa. Nature, 419:90–94.
13.
BompianiKM, LohrmannJL, PitocGA, FrederiksenJW, MackensenGB and SullengerBA. (2014). Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation. Chem Biol, 21:935–944.
14.
BelA, BorikW, DavidsonS, HeliesJM, StimmerL, FremesS, ZelenkofskeS, RusconiC, AlexanderJ, et al. (2016). Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. Eur J Cardiothorac Surg, 49:682–689.
15.
BuddaiSK, LayzerJM, LuG, RusconiCP, SullengerBA, MonroeDM and KrishnaswamyS. (2010). An anticoagulant RNA aptamer that inhibits proteinase-cofactor interactions within prothrombinase. J Biol Chem, 285:5212–5223.
16.
IbaT, LevyJH, LeviM and ThachilJ. (2020). Coagulopathy in COVID-19. J Thromb Haemost, 18:2103–2109.
17.
LeentjensJ, van HaapsTF, WesselsPF, SchutgensREG and MiddeldorpS. (2021). COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year. Lancet Haematol, 8:e524–e533.
18.
GiannisD, ZiogasIA and Gianni.P (2020). Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol, 127:104362.
19.
NougierC, BenoitR, SimonM, Desmurs-ClavelH, MarcotteG, ArgaudL, DavidJS, BonnetA, NegrierC and DargaudY. (2020). Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost, 18:2215–2219.
20.
de la Morena-BarrioME, Bravo-PerezC, MinanoA, de la Morena-BarrioB, Fernandez-PerezMP, BernalE, Gomez-VerduJM, HerranzMT, VicenteV, et al. (2021). Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients. Sci Rep, 11:7792.
21.
RanucciM, SitziaC, BaryshnikovaE, Di DeddaU, CardaniR, MartelliF and Corsi RomanelliM. (2020). Covid-19-associated coagulopathy: biomarkers of thrombin generation and fibrinolysis leading the outcome. J Clin Med, 9:3487.
22.
BouckEG, DenormeF, HolleLA, MiddeltonEA, BlairAM, de LaatB, SchiffmanJD, YostCC, RondinaMT, et al. (2021). COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity. Arterioscler Thromb Vasc Biol, 41:401–414.
23.
HardyM, MichauxI, LessireS, DouxfilsJ, DogneJM, BareilleM, HorlaitG, BulpaP, ChapelleC, et al. (2020). Prothrombotic hemostasis disturbances in patients with severe COVID-19: individual daily data. Data Brief, 33:106519.
24.
ZhaoX and CourtneyJM. (2011). Surface modification of biomaterials by heparinisation to improve blood compatibility. Surface Modification of Biomaterials: Methods Analysis and Applications, pp. 56–77.
25.
ConnersMS, 3rd and MoneySR. (2002). The new heparins. Ochsner J, 4:41–47.
26.
OneyS, LamRT, BompianiKM, BlakeCM, QuickG, HeidelJD, LiuJY, MackBC, DavisME, et al. (2009). Development of universal antidotes to control aptamer activity. Nat Med, 15:1224–1228.
27.
LeeGM, WelsbyIJ, Phillips-ButeB, OrtelTL and ArepallyGM. (2013). High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. Blood, 121:2828–2835.
28.
EdmundsLHJr. and ColmanRW. (2006). Thrombin during cardiopulmonary bypass. Ann Thorac Surg, 82:2315–2322.
29.
ConnorsJM and LevyJH. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood, 135:2033–2040.
30.
CarterCA, SkoutakisVA, SpiroTE, WestME, ToomsRE, JoeRH and KnutsonTJ. (1993). Enoxaparin: the low-molecular-weight heparin for prevention of postoperative thromboembolic complications. Ann Pharmacother, 27:1223–1230.
31.
ElbeddiniA, GerochiR and Elshahawi.A (2020). Evaluation of the prophylaxis and treatment of COVID-associated coagulopathy. J Pharm Policy Pract, 13:73.
32.
MurphyDA, HockingsLE, AndrewsRK, AubronC, GardinerEE, PellegrinoVA and DavisAK. (2015). Extracorporeal membrane oxygenation-hemostatic complications. Transfus Med Rev, 29:90–101.
33.
RaitenJM, WongZZ, SpeldeA, LittlejohnJE, AugoustidesJGT and GutscheJT. (2017). Anticoagulation and transfusion therapy in patients requiring extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth, 31:1051–1059.
34.
GuoZ, SunL, LiB, TianR, ZhangX, ZhangZ, CliffordSP, LiuY, HuangJ and LiX. (2021). Anticoagulation management in severe coronavirus disease 2019 patients on extracorporeal membrane oxygenation. J Cardiothorac Vasc Anesth, 35:389–397.
35.
GratzJ, PauschA, SchadenE, BaierlA, JakschP, ErhartF, HoetzeneckerK and WiegeleM. (2020). Low molecular weight heparin versus unfractioned heparin for anticoagulation during perioperative extracorporeal membrane oxygenation: a single center experience in 102 lung transplant patients. Artif Organs, 44:638–646.
36.
FareedJ, HoppensteadtD, WalengaJ, IqbalO, MaQ, JeskeW and SheikhT. (2003). Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet, 42:1043–1057.
37.
AbdelfattahK and CrippsMW. (2016). Thromboelastography and rotational thromboelastometry use in trauma. Int J Surg, 33:196–201.
38.
HemkerHC, GiesenP, Al DieriR, RegnaultV, de SmedtE, WagenvoordR, LecompteT and BeguinS. (2003). Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb, 33:4–15.
39.
WeitzJI, HudobaM, MasselD, MaraganoreJ and HirshJ. (1990). Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest, 86:385–391.
40.
WeitzJI and BullerHR. (2002). Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation, 105:1004–1011.
41.
LiuCY, NosselHL and KaplanKL. (1979). The binding of thrombin by fibrin. J Biol Chem, 254:10421–10425.
42.
RohDJ, EisemanK, KirschH, YohN, BoehmeA, AgarwalS, ParkS, ConnollyES, ClaassenJ and WagenerG. (2021). Hypercoagulable viscoelastic blood clot characteristics in critically ill coronavirus disease 2019 patients and associations with thrombotic complications. J Trauma Acute Care Surg, 90:e7–e12.
43.
SakrY, GioviniM, LeoneM, PizzilliG, KortgenA, BauerM, TonettiT, DuclosG, ZieleskiewiczL, et al. (2020). Pulmonary embolism in patients with coronavirus disease-2019 (COVID-19) pneumonia: a narrative review. Ann Intensive Care, 10:124.
44.
KowalewskiM, FinaD, SlomkaA, RaffaGM, MartucciG, Lo CocoV, De PieroME, RanucciM, SuwalskiP and Lorusso.R (2020). COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review. Crit Care, 24:205.
45.
RamanathanK, AntogniniD, CombesA, PadenM, ZakharyB, OginoM, MacLarenG, BrodieD and ShekarK. (2020). Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med, 8:518–526.
46.
SusenS, TacquardCA, GodonA, MansourA, GarrigueD, NguyenP, GodierA, TestaS, LevyJH, et al. (2020). Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit Care, 24:364.
47.
HasijaS, TalwarS, MakhijaN, ChauhanS, MalhotraP, ChowdhuryUK, KrishnaNS and SharmaG. (2018). Randomized controlled trial of heparin versus bivalirudin anticoagulation in acyanotic children undergoing open heart surgery. J Cardiothorac Vasc Anesth, 32:2633–2640.
48.
TanakaKA, SzlamF, SunHY, TaketomiT and LevyJH. (2007). Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. Anesth Analg 105:933–939, table of. contents.
49.
FronteraJA, BhattP, LalchanR, YaghiS, AhujaT, PapadopoulosJ and JosetD. (2020). Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage. J Thromb Thrombolysis, 49:121–131.
50.
KhadkaS, KasireddyV and Dhakal.P (2020). Institutional experience of using andexanet alfa. Cureus, 12:e9173.
51.
(2018). Andexxa—an antidote for apixaban and rivaroxaban. Med Lett Drugs Ther, 60:99–101.
52.
VilanovaE, TovarAMF and MouraoPAS. (2019). Imminent risk of a global shortage of heparin caused by the African Swine Fever afflicting the Chinese pig herd. J Thromb Haemost, 17:254–256.
53.
BengeCD and BurkaAT. (2019). Heparin drug shortage conservation strategies. Fed Pract, 36:449–454.
54.
ArepallyGM and OrtelTL. (2010). Heparin-induced thrombocytopenia. Annu Rev Med, 61:77–90.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
